uniform_resource_study (table) Content

DCLP1 Randomized Controlled Trial of Mobile Closed-Loop Control 2017-11-01 2018-05-01 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant UC4-DK-108483. NCT02985866 This protocol, NCT02985866, is a 3-month parallel group, multicenter, randomized unblinded trial designed to comparemobile CLC with sensor augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ‡14 years, and baseline HbA1c <10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. UVA001